GET DAILY SIGNALSEnovis (ENOV) Delivers +17% EPS Beat and Raises Full-Year Guidance
Key Takeaways
- Enovis reported third-quarter net sales of $558.7 million, up 1.8% year over year (5% organic), essentially in line with consensus estimates.
- Adjusted earnings per share (EPS) came in at $0.88, up 17% year over year and comfortably above the roughly $0.77 Wall Street consensus.
- Adjusted EBITDA rose to $103.5 million, an 18.5% margin, up 120 basis points year over year.
- Management raised full-year guidance for adjusted EBITDA and adjusted EPS and narrowed its revenue outlook, while announcing a new $200 million share repurchase authorization.
- The pending acquisition of eCential Robotics remains on track to close by year-end, positioning the company to bring a knee robot to market within roughly two years.
Putting the Quarter in Context
Enovis Corporation (ENOV), a global medical technology company focused on orthopedic reconstruction and prevention-and-recovery products, has been working to convert steady organic growth into better profitability. The third-quarter report provides a useful test of whether the company can maintain share gains in its Reconstructive segment amid a mixed procedural backdrop, cost pressures, and currency swings. Last year’s comparable period included a sizable goodwill impairment, so the emphasis now is on underlying operational trends rather than headline GAAP results. The print also followed closely on the heels of the planned eCential Robotics acquisition, offering a checkpoint on both near-term execution and longer-term innovation plans.
Breaking Down the Reported Results
For the fiscal third quarter ended October 2, 2026, ENOV posted net sales of $558.7 million, up 1.8% year over year on a reported basis and 5% organically. Revenue came in essentially in line with consensus estimates of about $557.8 million. Reported growth reflected a foreign-currency headwind and the effect of the Dr. Comfort divestiture.
Segment performance showed Reconstructive sales growing 6% organically and Prevention & Recovery sales advancing 3% organically. Adjusted EBITDA reached $103.5 million for an 18.5% margin, up 120 basis points from the prior year. Adjusted EPS of $0.88 represented a 17% year-over-year increase and exceeded the consensus estimate of roughly $0.77. On a GAAP basis, the company recorded net income of $3.4 million, or $0.02 per diluted share from continuing operations.
Management also updated its full-year outlook. Revenue guidance was tightened to $2.32–$2.35 billion, adjusted EBITDA guidance was lifted to $428–$438 million, and adjusted EPS guidance was raised to $3.58–$3.79. Free cash flow conversion is still projected at 25% or higher.
How the Market Responded
Shares of ENOV rose roughly 9.8% in the immediate aftermath of the release. The reaction appeared to reflect relief that adjusted EPS significantly beat expectations and that full-year profitability targets were increased. Investors focused on the margin expansion in adjusted EBITDA, the earnings beat, and the new $200 million buyback authorization as signs of management confidence.
Some notes of caution were also present. U.S. hip and knee growth of 3% trailed extremities and international trends, while the Middle East conflict created an approximate 100-basis-point drag on international growth. Part of the EPS outperformance was offset by planned fourth-quarter investments and currency effects, which tempered the flow-through to guidance. Overall, the tone stayed constructive, underscoring that investors are rewarding progress on profitability and cash generation alongside top-line results.
What I’m Watching Next
Looking forward, ENOV anticipates a modest acceleration in both segments in the fourth quarter, supported by new product momentum. The company highlighted continued strength in the ARVIS augmented-reality platform, ongoing Nebula stem conversions, and fresh Prevention & Recovery introductions. Management’s outlook assumes the procedural environment seen in the third quarter persists through year-end, along with typical seasonality.
Several items merit close attention. Completion of the eCential Robotics acquisition, expected by year-end, remains central to the long-term robotics strategy in knee and shoulder procedures. Free cash flow is another focus, with management signaling a step-up to at least 50% conversion next year and roughly $100 million in cash generation—an improvement that supports the new repurchase program.
Cost and margin dynamics also warrant monitoring. Tariff refunds and operational productivity helped gross margin in the third quarter, yet inflationary pressures on raw materials, freight, and distribution continue to offset some gains. Balancing incremental research and development spending with margin discipline, and the evolution of the leverage profile after the eCential close, will be key themes when fourth-quarter and full-year results are reported in February.
Integrating AI Tools into My Process
When I review earnings-driven moves like this one, I often run quick screens with Tickeron’s AI Screener to compare ENOV against peers on fundamentals, volatility, and recent patterns. The tool helps surface relevant names efficiently and supports building a more systematic watchlist without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ENOV in upward trend: 10-day moving average broke above 50-day moving average on October 27, 2026
The 10-day moving average for ENOV crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 70 cases where ENOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ENOV as a result. In 57 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
ENOV moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +18.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENOV advanced for three days, in 154 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
ENOV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ENOV entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. ENOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.953) is normal, around the industry mean (4.338). P/E Ratio (-1.265) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.466) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of fluid handling and industrial positioning products
Industry MedicalNursingServices
Advertisement